Cathie Wood's position in CRISPR Therapeutics AG is currently worth $599 Million. That's 3.62% of their equity portfolio (8th largest holding). The investor owns 10.01% of the outstanding CRISPR Therapeutics AG stock. The first CRISPR Therapeutics AG trade was made in Q2 2017. Since then Cathie Wood bought shares seventeen more times and sold shares on nine occasions. The investor's estimated purchase price is $606 Million, resulting in a loss of 1.1%.
Cathie Wood stocks make headlines for their potential to be at the leading edge of disruptive technologies and generate high returns. Yet, Wood’s flagship AR...
InvestorPlace, about 1 month agoThe innovation investor said her biotech darling CRISPR Therapeutics in the multiomics space has the potential to be her top performer next year.
CNBC, 3 months agoWood has outperformed the market so far this year.
The Motley Fool, 6 months agoCathie Wood had a rough few years. Her flagship fund, the ARK Innovation ETF (NYSEARCA: ARKK ), hit an all-time high of $156 in 2021 before crashing back to ...
InvestorPlace, 8 months ago